Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Continues To Find New Uses For Botox: Cleared For Chronic Migraine In The UK

This article was originally published in The Pink Sheet Daily

Executive Summary

30 injections around the head needed to control chronic migraines with Botox.

You may also be interested in...



Botox For Migraine: How Will The Market Size Up?

The U.S. approval of Allergan Inc.’s Botox (onabotulinumtoxinA) to treat chronic migraines will surely be a boon to the company, but anyone attempting to pin down the market impact of the approval will encounter enough variables to cause a splitting headache.

Botox For Migraine: How Will The Market Size Up?

The U.S. approval of Allergan Inc.’s Botox (onabotulinumtoxinA) to treat chronic migraines will surely be a boon to the company, but anyone attempting to pin down the market impact of the approval will encounter enough variables to cause a splitting headache.

Class REMS For Botulinum Toxin Products Warns Against Interchangeabilty

FDA announced a class-wide REMS for botulinum toxin products that focuses on the dangers on interchangeability of the drugs.

Related Content

Topics

UsernamePublicRestriction

Register

PS070877

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel